

**Brilliant Violet 421™ anti-mouse CD16/32**

**Catalog # / Size:** 1106660 / 50 µg  
1106655 / 125 µl

**Clone:** 93

**Isotype:** Rat IgG2a, λ


**Immunogen:** Sorted pre-B cells

**Reactivity:** Mouse

**Preparation:** The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421™ under optimal conditions. The solution is free of unconjugated Brilliant Violet 421™ and unconjugated antibody.

**Formulation:** Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).

**Concentration:** Lot-specific



C57BL/6 mouse splenocytes were stained with CD16/32 (clone 93) Brilliant Violet 421™ or rat IgG2a Brilliant Violet 421™ isotype control.

**Applications:**

**Applications:** Flow Cytometry

**Recommended Usage:** Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤5 microL per million cells or 5 microL per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

**Application Notes:** Clone 93 can be used for blocking of CD16/CD32 interactions with the Fc domain of immunoglobulins, but is not the same clone as 2.4G2.

The 93 mAb is specific to the common epitope of CD16/CD32. Additional reported applications (for the relevant formats) include: immunoprecipitation<sup>1</sup> and blocking of Fc-mediated reactions in functional studies<sup>2,4,23</sup>. It is useful for blocking non-specific binding of immunoglobulin to Fc receptors. For blocking of Fc receptors in flow cytometric analysis, pre-incubate the cells with purified anti-CD16/CD32 antibody (≤1.0 microg per 10<sup>6</sup> cells in 100 microL volume) for 5-10 minutes on ice prior to immunostaining. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 101310). For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 101330) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/microg).

- Application** 1. Personal communication (IP)
- References:** 2. Oliver AM, *et al.* 1999. *Hybridoma* 18:113. (Block)  
3. Brummel R and Lenert P. 2005. *J. Immunol.* 174:2429.  
4. Terrazas LI, *et al.* 2005. *Int. J. Parasitol.* 35:1349. (Block)  
5. Clements JL, *et al.* 2006. *J. Immunol.* 177:905.  
6. Mohamed W, *et al.* 2010. *Infect Immun.* 78:3306. [PubMed](#)  
7. Ouchi T, *et al.* 2011. *J. Exp Med.* 208:2607. [PubMed](#)  
8. Kmiecik M, *et al.* 2011. *J. Vis. Exp.* 47:2381. [PubMed](#)  
9. Yamazaki S, *et al.* 2012. *PLoS One.* 7:e51665. [PubMed](#)  
10. Li J, *et al.* 2012. *Arthritis Rheum.* 64:1098. [PubMed](#)  
11. Azuma M, *et al.* 2012. *Oncoimmunology.* 1:581. [PubMed](#)  
12. Koon HW, *et al.* 2013. *J. Vis. Exp.* 68:4208. [PubMed](#)  
13. Hegde VL, *et al.* 2013. *J Biol Chem.* 288:36810. [PubMed](#)  
14. Huang J, *et al.* 2013. *J. Immunol Methods.* 387:254. [PubMed](#)  
15. Dutow P, *et al.* 2014. *J Infect Dis.* [PubMed](#)  
16. Fan Y, *et al.* 2014. *J Exp Med.* 211:313. [PubMed](#)  
17. Huang HN, *et al.* 2014. *Antimicrob Agents Chemother.* 58:1538. [PubMed](#)  
18. Takei S, *et al.* 2014. *Vaccine.* 32:3066. [PubMed](#)  
19. Richardson ML, *et al.* 2014. *PLoS Negl Trop Dis.* 8:2825. [PubMed](#)  
20. Cekanaviciute E, *et al.* 2014. *J Immunol.* 193:139. [PubMed](#)  
21. Kimura T, *et al.* 2014. *Int Immunol.* 26:697. [PubMed](#)  
22. Everad A, *et al.* 2014. *Nat Commun.* 5:5648. [PubMed](#)  
23. Cenci E, *et al.* 2006. *J. Leuko. Biol.* 79(1):40-5. (Block)
- 

**Description:** CD16 is low affinity IgG Fc receptor III (FcR III) and CD32 is FcR II. CD16/CD32 are expressed on B cells, monocytes/macrophages, NK cells, granulocytes, mast cells, and dendritic cells. The Fc receptors bind antibody-antigen immune complexes and mediate adaptive immune responses.

- Antigen** 1. Barclay AN, *et al.* 1997. The Leukocyte Antigen FactsBook Academic Press.
- References:** 2. Unkeless JC. 1989. *J. Clin. Invest.* 83:355.  
3. Qiu WQ, *et al.* 1990. *Science* 248:732.